This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1978, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals. With a strong focus on high-quality, affordable medications, Par Pharmaceutical serves a diverse range of therapeutic areas, including oncology, pain management, and anti-infectives. The company is recognised for its commitment to innovation, particularly in the production of complex generics and niche products that meet specific patient needs. Par Pharmaceutical has achieved significant milestones, including strategic partnerships and a robust pipeline of products that enhance its market position. With a dedication to excellence and patient care, Par Pharmaceutical continues to make a meaningful impact in the healthcare landscape.
DitchCarbon Score
How does Par Pharmaceutical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Par Pharmaceutical, Inc.'s score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Par Pharmaceutical, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Endo Inc., which means that any emissions data or climate commitments may be inherited from its parent organisation. As of now, there are no documented reduction targets or climate pledges specific to Par Pharmaceutical. The absence of specific emissions data suggests that the company may be in the early stages of developing its climate strategy or reporting framework. Given its relationship with Endo Inc., any relevant climate initiatives or emissions data would likely be aligned with the broader commitments of the parent company. However, without specific figures or targets from Par Pharmaceutical, it is challenging to provide a detailed overview of its carbon footprint or climate commitments. In summary, while Par Pharmaceutical, Inc. does not currently report specific emissions data or reduction targets, it is positioned within a corporate structure that may influence its future climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Par Pharmaceutical, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
